Särnefält Anna, Eardley-Patel Ranna, Magini Diletta, Sonje Vishal, Guzzi Antonio, Hesselink Renske, Scotney Matthew, Lazdins Alessandro, Chambard Valerie, Vinnemeier Christof, Kromann Ingrid
Coalition for Epidemic Preparedness Innovations (CEPI), 0218 Oslo, Norway
Coalition for Epidemic Preparedness Innovations (CEPI), 0218 Oslo, Norway.
PDA J Pharm Sci Technol. 2024 Oct 22;78(5):613-623. doi: 10.5731/pdajpst.2023.012912.
The Coalition for Epidemic Preparedness Innovations (CEPI) has developed a robust CMC (Chemistry, Manufacturing, and Controls) Framework to enhance the likelihood of successful vaccine development. This Framework serves as a comprehensive guide, aiding developers in building effective strategies to overcome the challenges posed by the different phases of vaccine development, including the ones often referred to as the "valleys of death". The Framework lists stage-appropriate deliverables, categorized and refined, spanning five key areas: manufacturing process, formulation and stability, analytics, supply chain, and compliance. By emphasizing the critical aspects of CMC development, CEPI's objective is to expedite the progression of vaccine candidates from research to deployment, reducing delays, mitigating risks, and optimizing the overall development process, all while upholding uncompromising quality standards, ultimately increasing the probability of success.
流行病防范创新联盟(CEPI)已制定了一个完善的化学、制造与控制(CMC)框架,以提高疫苗成功开发的可能性。该框架作为一份全面的指南,帮助开发者制定有效的策略,以克服疫苗开发不同阶段所带来的挑战,包括那些常被称为“死亡谷”的阶段。该框架列出了适合各阶段的可交付成果,这些成果经过分类和细化,涵盖五个关键领域:制造工艺、配方与稳定性、分析、供应链和合规性。通过强调CMC开发的关键方面,CEPI的目标是加快候选疫苗从研究到部署的进程,减少延误、降低风险并优化整体开发过程,同时坚持不妥协的质量标准,最终提高成功的概率。